Tulane Cancer Center
Tulane University School of Medicine
New Orleans, LA
Accepting patients
Etentamig
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 1
- Has results